We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 66,058 | 07:34:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/10/2016 21:04 | Mindful of the fact that readers seem to be a bit thick, I will ensure that my report is not even remotely complex to enable these sorts to digest the same. | yasx | |
05/10/2016 21:00 | Bluebull, I hope so - I will take more still. | yasx | |
05/10/2016 21:00 | Chewin, The £5 target is a rather conservative one- I will set out my findings over the next few days. You say these vehicles need to be listed separately, and that is a pathway that might in due course be pursued. Separately, it is likely that when/if funding arrangements are secured for the two aforementioned parts of the Group, well, that will in itself provide a quantitative assessment of the likely value of each (of course, it all depends how the funding is prescribed, but it will certainly give a good idea). I am fairly sure over time the various vehicles will either be listed separately, or get taken out prior to so doing. It all hinges on the likelihood of these demonstrating a tangible route to commercialisation through a good offering and associated take up. I reckon, on the balance of probabilities, they will - they have leading experts attach to each of the Groups, and these are carefully being steered in the right direction - more in my report. This is a delightful opportunity, and as yet not many (save Woodford) have spotted it. He got in far too early before the Group was re-structured, but now is the time, in my view, to gobble up these shares before the market recognises the opportunity. | yasx | |
05/10/2016 20:54 | Waterloo, No, they did not - you are confused as a result of a mistaken interpretation of the actual published material. Allow me to elucidate. The only two parts of the Group that I recall require funding are Proaxiss and Glycotest. Proaxiss requires funding for the neutrophil elastase (a part of ProaXISS), which is distinctly different to funding for the wider Group NSCI. Additionally, Glycotest is imminently aiming to secure a financing deal (by the end of this year). Both of these are funding arrangements that will serve as positive catalysts, and not dilute holders of equity of NSCI. Depending on the nature of the funding arrangement, it will likely follow that NSCI's stake in each of these component Groups gets reduced in exchange for whatever funds are tabled, but that is no bad thing but a very positive move to accelerate both Glycotest and Proaxiss. Readers really need to grasp the basics prior to offering any opinion. I will publish a very detailed report by the end of this week. It will set out why this is going much, much higher (in my view at least). I might be wrong, but I doubt it. | yasx | |
05/10/2016 19:58 | Back to 70p..? | blueball | |
05/10/2016 19:38 | Typical Yazx nonsense.Costs are rising here, I'm interested to watch how you get interest, since I remember from last summer you pumping this on the TPL board.My six sense detects you are a bit uneasy at present, tell the board to get some of these entities listed.Quite obvious when this is ramped it will move quickly as its so illiquid, that seems to be your game?Where is your research to back up your £5 'plucked from the air' figure? | che7win | |
05/10/2016 19:35 | Didn't they say they needed to raise funds this half? Better wait till after? | waterloo01 | |
05/10/2016 19:29 | The tremendous thing abut this stock is that it is not yet on the radar of any momentum investors. There was substantial interest from the Woodford fund, but there is no awareness with the broader market participants. The Company is not really building upon the early interest since it would appear to me they are seeking to ensure all the pieces are properly prepared and that the jigsaw is ready to be assembled. It is nearly at that point, and when the market gets a sniff, mark my words, it will give rise to gains, and rather a lot of them. Incidentally, there will be external funding for one or two of the arms per earlier suggestions - quite what the quantum/metrics of any transaction remains to be seen, but even one deal can transform the shareprice and I expect there will be more than one deal going forward. | yasx | |
05/10/2016 19:24 | Chewin suggests the chart curve (sagacious readers will not be familiar with such a technical term since it is not in any charting manual that one might encounter) is intact - what is not intact , however, is that brain of his. That, I opine, he left in the cupboard with the biscuits. | yasx | |
05/10/2016 19:22 | Chewin, What you know about this (or indeed any other) company can be distilled on the back of a postage stamp. You are a novice, and you merely follow this gracious chap and hence why you have landed here. But, you are not welcome and can therefore disappear with great ease. As regards NSCI, I point out to other readers that this is now at a clear turning point in terms of the various parts of the business. My analysis leads me to conclude that each of the several parts can command the current market capitalisation and more. It just needs the revenue streams to start motoring, but, given the businesses have made great strides over the past few months, the monetisation of these assets will begin shortly - indeed, many of the nascent stages have already been ticked. More to come - target remains beyond £5. | yasx | |
05/10/2016 16:54 | The chart curve still intact.If this moves, it will move very quick, I guess it needs news flow.NTQ interests me. | che7win | |
05/10/2016 16:48 | No problem chewin I did not go overboard by any stretch of the imagination Very small holding and if it drops no problem whatsoever I can buy more if I fancy a tipple. Best Escape. | escapetohome | |
05/10/2016 14:38 | Escape, Think you've been sold a pup here. .. | che7win | |
04/10/2016 16:30 | This has an interesting curve developing... | che7win | |
04/10/2016 16:29 | Cheers escape, NTQ, I've been watching that as well as here.GMS might also prove interesting to you in that case, a similar play on oil recovery, although debt quite high. | che7win | |
04/10/2016 16:17 | Hello chew7win Nice to see you on here. Ive got a few here but put most into NTQ, on account that the rig count is slowly in uptick mode and the worst is over. Saw your tips on the iof thread, but not rushing in on any yet. | escapetohome | |
04/10/2016 14:08 | That 22.5k is a buy, what's up escape?You in this one? | che7win | |
30/9/2016 08:42 | Another milestone at one of the companies in the portfolio... All chips are lining up rather nicely indeed. | yasx | |
29/9/2016 08:50 | mr 4815 in yesterday@79 out today for 74 £250 smackers down the swanny.adios. | runwaypaul | |
28/9/2016 10:16 | settling back into oblivion... zzzzzzzzzzzzzzzzzzzz | runwaypaul | |
27/9/2016 20:14 | . i'll edit that as well. | runwaypaul | |
27/9/2016 20:13 | Take the last 4 words off and it and pin in on your wall. Look at it then bang your head on your desk 4 times before making any trades.Ciao for now. | beeks of arabia | |
27/9/2016 20:10 | Beeks of Arabia - 18 Sep 2016 - 15:45:31 - 450 of 467 Generally best to leave the research to others if you don't know what you are doing, that's my investment strategy pmsl Yasx put your money where your mouth is and buy some more in the morning then.if you can afford too,may help liquidity.atb | runwaypaul |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions